贝塔阻塞剂在心力衰竭中具有减少的喷射分数:对随机对照试验的系统审查
Sara Elmobark1, Fouad Hamad2, Lemia Gameil Hassan Mutwali3
1Internal Medicine, Aberdeen Royal Infirmary, Aberdeen, GBR.
Cureus
|October 1, 2025
概括
β-阻塞剂显著降低了心力衰竭的死亡率,减少了喷射分数 (HFrEF). 然而,它们对心肌梗塞 (MI) 后患有保存的喷射分数 (EF) 的患者显示出有限的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 系统审查是系统的审查.
背景情况:
- 减少喷射率 (HFrEF) 的心力衰竭是全球主要的健康问题.
- β抑制剂是HFrEF的主要治疗方法,改善了患者的治疗结果.
- 贝塔抑制剂在心肌梗塞 (MI) 后患有保留喷射分数 (EF) 的患者中所起的作用尚未得到充分证实.
研究的目的:
- 系统地审查β-阻断剂在HFrEF和后心脏病发作患者的临床影响.
- 为了澄清β-阻断剂在不同心血管患者表型中的作用.
- 根据射出分数状态来评估β-阻断剂的疗效.
主要方法:
- 按照PRISMA指南进行的八项随机对照试验 (RCT) 的系统审查.
- 由两个独立审查员提取数据,包括对死亡率,住院和EF变化的评估.
- 由于异质性,使用Cochrane RoB 2工具和叙事综合评估偏差风险.
主要成果:
- 在慢性HFrEF患者中,β抑制剂显著降低了全因死亡率和心力衰竭住院治疗.
- 在心脏病发作后的患者中,β阻断剂对死亡率和心血管结果具有中性影响.
- 在这两组患者中,β-阻断剂的安全性概况是有利的,没有报告过多的不良事件.
结论:
- β-阻断剂是高度有效的,并推给HFrEF患者.
- 在心脏病发作后患者中常规使用β-阻塞剂,并保留EF,其益处有限.
- 这些发现支持心血管医学中的表型特异性治疗策略.
更多相关视频
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.0K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.0K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
771
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
771
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
01:28Antihypertensive Drugs: Types of β-Blockers
1.5K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.5K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K